LYTGOBI (futibatinib) is a targeted kinase inhibitor designed for the treatment of patients with specific genetic alterations in their tumors, particularly FGFR2 gene fusions or rearrangements. It is administered orally as a 4 mg tablet, with the recommended dose being 20 mg (five 4 mg tablets) taken once daily. This therapy is specifically aimed at addressing the needs of patients with advanced intrahepatic cholangiocarcinoma who have failed previous treatment options.

The drug operates by inhibiting fibroblast growth factor receptor 2 (FGFR2), a protein involved in tumor growth and progression. By targeting this pathway, LYTGOBI aims to reduce tumor size and prevent further disease progression. The clinical use of LYTGOBI requires confirmation of the presence of FGFR2 gene alterations prior to starting therapy, and treatment should be continued until disease progression or unacceptable toxicity occurs. Ongoing monitoring for ocular toxicity and other side effects is crucial for ensuring patient safety during treatment.